Prof. Jianchuan Xia 夏建川
Chief Physician, Professor
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Tumor etiology and immune cell therapy. Focuses on basic and clinical applications of immunotherapy for malignancies including nasopharyngeal, lung, breast, gastric, colorectal, liver, and kidney cancers.
Dr. Xia holds a medical doctorate from Harbin Medical University (1998) and completed postdoctoral research at Harvard Dana-Farber Cancer Institute (2000–2003). As Director of the Biotherapy Center at Sun Yat-sen University Cancer Center, Dr. Xia leads research in tumor immunology and established national standards for autologous immune cell therapy. Dr. Xia has authored textbooks and published extensively in journals such as Nature Genetics and The Journal of Immunology.
Professional roles
- Chair, Asia-Pacific Medical Student Biological Immunity Society
- Chair, China Cell Therapy Quality Control and Research Professional Committee
- Vice Chair, Chinese Research Hospital Association Biotherapy Professional Committee
- Editorial Board Member, Cancer Letter (US)
Name order: in Chinese the family name comes first (Xia Jianchuan). Papers usually list the name as Jianchuan Xia or Xia J.
Selected publications
127 papers on PubMed matched by name and affiliation; 52 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Sci (Weinh), 2026 (senior author): HNRNPD Induces Radioresistance in Nasopharyngeal Carcinoma by Sequestering GRAMD4 mRNA in Stress Granules. PubMed 42107076
- J Immunother Cancer, 2026 (senior author): CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3-TGF-β signaling pathway. PubMed 42538053
- Pharmacol Res, 2026 (senior author): Blockade of the CLCF1-CNTFR axis enhances the efficacy of GPC3 CAR-T cell therapy in hepatocellular carcinoma. PubMed 42102942
- Adv Sci (Weinh), 2025 (senior author): The CXCL10-CXCR3 Axis Induces Tumor-Associated Neutrophils to Interfere with CTLs-Mediated Antitumor Activity in EBV-Associated Epithelial Cancers. PubMed 40686457
- Front Immunol, 2024 (senior author): TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC. PubMed 39726591
- Theranostics, 2024 (senior author): EBV-associated epithelial cancers cells promote vasculogenic mimicry formation via a secretory cross-talk with the immune microenvironment. PubMed 39267775
- Mol Cancer Ther, 2024 (senior author): SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity. PubMed 38647536
- Oncogene, 2024 (senior author): Epstein-Barr virus causes vascular abnormalities in epithelial malignancies through upregulating ANXA3-HIF-1α-VEGF pathway. PubMed 38778160
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion